Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024

2024-03-14
PRNewswire
AACR会议
Findings highlight tolerability and pharmacology of MTX-101 in humanized IL–15 transgenic mouse model
SEATTLE, March 14, 2024 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases, today announce new non-clinical data for MTX-101. The data will be presented in a late-breaking poster presentation during the Society of Toxicology 63rd Annual Meeting, March 10‒14 in Salt Lake City, Utah.
MTX-101 is an antibody-based bispecific autoimmune checkpoint inhibitor that selectively targets regulatory CD8 T cells. MTX-101 has limited cross-reactivity to its targets in animal models; therefore, a humanized IL-15 transgenic mouse model was utilized for non-clinical assessment of toxicity and pharmacology.
Presentation highlights include:
MTX-101 was well-tolerated following single and multiple doses in the humanized mouse model
MTX-101 showed sustained binding to CD8 Treg and did not demonstrate off-target cell effects or cause an increase in detectable pro-inflammatory serum cytokines
Serum concentrations of MTX-101 indicated high exposure and PK parameters consistent with antibodies
Data derived from the humanized mouse model aligns with previous in vitro and in vivo findings for MTX-101
"We are pleased to present early data highlighting the non-clinical safety of MTX-101. Our data underline the utility of the humanized IL-15 transgenic mouse model to assess targeting human immune system receptors with limited cross-reactivity in conventional toxicology species," said Kristine Swiderek, Ph.D., Chief Scientific Officer at Mozart Therapeutics. "This model enables the non-clinical safety assessment and an understanding of the PK/PD relationship for MTX-101 to inform our clinical development strategy."
The poster "Nonclinical Assessment of Toxicity and Pharmacology of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator, in Humanized Mouse"
(Abstract #5081, Late-Breaking Session 3, March 14) can be accessed from the Mozart Therapeutics website.
About MTX-101
MTX-101 is a bispecific CD8 Treg modulator targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitorautoimmune checkpoint inhibitor aims to restore the intrinsic functions of regulatory CD8 T cells, acting early in the autoimmune disease process to suppress and eliminate pathogenic autoimmune cells, halt downstream inflammation, and prevent tissue destruction.
Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, utilizing a novel approach to restoring immune system function by targeting the CD8 T regulatory network. The company is headquartered in Seattle, WA. For more information, visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。